DiaGenic ASA to Partner with Opaldia in UK on Blood Based Breast Cancer Gene Expression Test

OSLO, Norway--(BUSINESS WIRE)--The Norwegian life sciences company, DiaGenic ASA today announced that it has signed a letter of intent with Opaldia concerning Opaldia becoming the commercial partner in the UK for its proprietary gene expression tests. The first is expected to be DiaGenic’s breast cancer test, which is aiming for CE mark approval by the end of 2008. The test will be made available in the UK to private patients as part of the Opaldia Breastcare Programme.